Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II concurrent chemoradiotherapy followed by PIDE for localized nasal NK/T-cell lymphoma
ChiCTR-OIC-17013701Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase, ifosfamide, dexamethasone, etoposide and cisplatin in extranodal natural killer/T-cell lymphoma (ENKTL) and Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Union Hospital. Primary endpoints: Progression-free survival, Overall survival and 1 more. Started Jan 2018; status: recruiting.
02
Drugs
pegaspargaseifosfamidedexamethasoneetoposidecisplatin
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR-OIC-17013701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013701.